Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2028

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

Control Group

Given by PO

DRUG

TTI-101

Given by PO

Trial Locations (1)

M D Anderson Cancer Centerl, Houston

All Listed Sponsors

collaborator

Tvardi Therapeutics, Inc

UNKNOWN

collaborator

National Institutes of Health (NIH)

NIH

lead

M.D. Anderson Cancer Center

OTHER